Literature DB >> 9577349

Expression of arylamine N-acetyltransferase in human intestine.

D Hickman1, J Pope, S D Patil, G Fakis, V Smelt, L A Stanley, M Payton, J D Unadkat, E Sim.   

Abstract

BACKGROUND: Arylamine N-acetyltransferases in humans (NAT1 and NAT2) catalyse the acetylation of arylamines including food derived heterocyclic arylamine carcinogens. Other substrates include the sulphonamide 5-aminosalicylic acid (5-ASA), which is an NAT1 specific substrate; N-acetylation of 5-ASA is a major route of metabolism. NAT1 and NAT2 are both polymorphic. AIMS: To investigate NAT expression in apparently healthy human intestines in order to understand the possible role of NAT in colorectal cancer and in the therapeutic response to 5-ASA.
METHODS: The intestines of four organ donors were divided into eight sections. DNA was prepared for genotyping NAT1 and NAT2 and enzymic activities of NAT1 and NAT2 were determined in cytosols prepared from each section. Tissue was fixed for immunohistochemistry with specific NAT antibodies. Western blotting was carried out on all samples of cytosol and on homogenates of separated muscle and villi after microdissection.
RESULTS: NAT1 activity of all cytosols was greater than NAT2 activity. NAT1 and NAT2 activities correlated with the genotypes of NAT1 and NAT2 and with the levels of NAT1 staining determined by western blotting. The ratio of NAT1:NAT2 activities showed interindividual variations from 2 to 70. NAT1 antigenic activity was greater in villi than in muscle. NAT1 was detected along the length of the villi in the small intestine. In colon samples there was less NAT1 at the base of the crypts with intense staining at the tips.
CONCLUSIONS: The interindividual variation in NAT1 and NAT2 in the colon could affect how individuals respond to exposure to specific NAT substrates including carcinogens and 5-ASA.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9577349      PMCID: PMC1727045          DOI: 10.1136/gut.42.3.402

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  33 in total

1.  Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver.

Authors:  T Deguchi; M Mashimo; T Suzuki
Journal:  J Biol Chem       Date:  1990-08-05       Impact factor: 5.157

2.  N-acetyltransferase 2 genotype in colorectal cancer and selective gene retention in cancers with chromosome 8p deletions.

Authors:  A L Hubbard; D J Harrison; C Moyes; A H Wyllie; C Cunningham; E Mannion; C A Smith
Journal:  Gut       Date:  1997-08       Impact factor: 23.059

Review 3.  Aetiology of colorectal cancer: current concepts.

Authors:  M J Hill
Journal:  Baillieres Clin Gastroenterol       Date:  1989-07

4.  Partial purification and properties of the isoniazid transacetylase in human liver. Its relationship to the acetylation of p-aminosalicylic acid.

Authors:  J W Jennne
Journal:  J Clin Invest       Date:  1965-12       Impact factor: 14.808

Review 5.  N-acetylation pharmacogenetics.

Authors:  W W Weber; D W Hein
Journal:  Pharmacol Rev       Date:  1985-03       Impact factor: 25.468

6.  Carcinogenicity of mutagenic heterocyclic amines formed during the cooking process.

Authors:  T Sugimura
Journal:  Mutat Res       Date:  1985 Jun-Jul       Impact factor: 2.433

7.  DNA adducts formed from the probable proximate carcinogen, N-hydroxy-3,2' -dimethyl-4-aminobiphenyl, by acid catalysis or S-acetyl coenzyme A-dependent enzymatic esterification.

Authors:  T J Flammang; J G Westra; F F Kadlubar; F A Beland
Journal:  Carcinogenesis       Date:  1985-02       Impact factor: 4.944

8.  Aromatic amine acetyltransferase as a marker for colorectal cancer: environmental and demographic associations.

Authors:  J C Wohlleb; C F Hunter; B Blass; F F Kadlubar; D Z Chu; N P Lang
Journal:  Int J Cancer       Date:  1990-07-15       Impact factor: 7.396

9.  Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases.

Authors:  D W Hein; M A Doll; T D Rustan; K Gray; Y Feng; R J Ferguson; D M Grant
Journal:  Carcinogenesis       Date:  1993-08       Impact factor: 4.944

10.  Kinetics of arylamine N-acetyltransferase in tissues from rapid and slow acetylator mice.

Authors:  S S Mattano; W W Weber
Journal:  Carcinogenesis       Date:  1987-01       Impact factor: 4.944

View more
  31 in total

1.  Identification and functional characterization of arylamine N-acetyltransferases in eubacteria: evidence for highly selective acetylation of 5-aminosalicylic acid.

Authors:  C Deloménie; S Fouix; S Longuemaux; N Brahimi; C Bizet; B Picard; E Denamur; J M Dupret
Journal:  J Bacteriol       Date:  2001-06       Impact factor: 3.490

2.  Kinetics of acetyl coenzyme A: arylamine N-acetyltransferase from human cumulus cells.

Authors:  C C Chang; Y Y Hsieh; J G Chung; H D Tsai; C H Tsai
Journal:  J Assist Reprod Genet       Date:  2001-09       Impact factor: 3.412

3.  Leukemia inhibitory factor decreases the arylamine N-acetyltransferase activity in human cumulus granulosa cells.

Authors:  C C Chang; Y Y Hsieh; J G Chung; H D Tsai; C H Tsai
Journal:  J Assist Reprod Genet       Date:  2001-12       Impact factor: 3.412

4.  N-Acetyltransferase polymorphism and human cancer risk.

Authors:  X Yang; T Takeshita; K Morimoto
Journal:  Environ Health Prev Med       Date:  2000-01       Impact factor: 3.674

Review 5.  Arylamine N-acetyltransferases: a structural perspective.

Authors:  Xiaotong Zhou; Zhiguo Ma; Dong Dong; Baojian Wu
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

6.  N-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulphasalazine in the treatment of inflammatory bowel disease.

Authors:  Min Chen; Bing Xia; Bixiao Chen; Qiusha Guo; Jin Li; Mei Ye; Zhengguo Hu
Journal:  Can J Gastroenterol       Date:  2007-03       Impact factor: 3.522

7.  Base-displaced intercalated structure of the food mutagen 2-amino-3-methylimidazo[4,5-f]quinoline in the recognition sequence of the NarI restriction enzyme, a hotspot for -2 bp deletions.

Authors:  Feng Wang; Nicholas E DeMuro; C Eric Elmquist; James S Stover; Carmelo J Rizzo; Michael P Stone
Journal:  J Am Chem Soc       Date:  2006-08-09       Impact factor: 15.419

8.  Mesalazine pharmacokinetics and NAT2 phenotype.

Authors:  Hendrik Lück; Martina Kinzig; Alexander Jetter; Uwe Fuhr; Fritz Sörgel
Journal:  Eur J Clin Pharmacol       Date:  2008-08-14       Impact factor: 2.953

9.  Acute murine colitis reduces colonic 5-aminosalicylic acid metabolism by regulation of N-acetyltransferase-2.

Authors:  Verónica Ramírez-Alcántara; Marshall H Montrose
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-04-17       Impact factor: 4.052

10.  Probing the catalytic potential of the hamster arylamine N-acetyltransferase 2 catalytic triad by site-directed mutagenesis of the proximal conserved residue, Tyr190.

Authors:  Xin Zhou; Naixia Zhang; Li Liu; Kylie J Walters; Patrick E Hanna; Carston R Wagner
Journal:  FEBS J       Date:  2009-10-23       Impact factor: 5.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.